The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Leukemia

• Publication date

  2009-10-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2009.182PMID 19812608
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

  2008cited by this paper
• Clinical Trials and Observations

  2008cited by this paper
• Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

  2008cited by this paper
• Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells

  2008cited by this paper
• Histone deacetylase inhibitors: molecular mechanisms of action

  2007cited by this paper
• Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group

  2007cited by this paper
• Histone Deacetylase Inhibitors: Overview and Perspectives

  2007cited by this paper
• Acute myeloid leukaemia.

  2006cited by this paper
• The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

  2006cited by this paper
• Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.

  2006cited by this paper
• Clinical development of histone deacetylase inhibitors as anticancer agents.

  2005cited by this paper
• Histone deacetylase inhibitors.

  2005cited by this paper
• Drug therapy for acute myeloid leukemia.

  2005cited by this paper
• Regulatory cross‐talk between lysine acetylation and ubiquitination: role in the control of protein stability

  2005cited by this paper
• Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

  2005cited by this paper
• Cell death: critical control points.

  2004cited by this paper
• Review Cell Death: Critical Control Points Another Line of Evidence for the Importance of Caspases in Cell Death Came From

  2004cited by this paper
• Regulation of histone deacetylase activities

  2004cited by this paper
• Histone deacetylase inhibitors.

  2003cited by this paper
• Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)*

  2003cited by this paper
• Chromatin Modification, Leukaemia and Implications for Therapy

  2002cited by this paper
• Histone deacetylase inhibitors induce caspase‐dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17)

  2001cited by this paper
• Histone deacetylases and cancer: causes and therapies

  2001cited by this paper
• Histone acetylation and disease

  2001cited by this paper
• Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen*

  2001cited by this paper
• Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

  2001cited by this paper
• Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1.

  2000cited by this paper
• Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.

  1999cited by this paper
• Role for Caspase-Mediated Cleavage of Rad51 in Induction of Apoptosis by DNA Damage

  1999cited by this paper
• A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.

  1999cited by this paper
• Acute myeloid leukaemia.

  1996cited by this paper
• The biochemistry of programmed cell death

  1995cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

  1973cited by this paper

• Epigenetic mechanisms of drug resistance in acute myeloid leukemia: advances in small-molecule targeted therapy

  2025cites this paper
• HDAC6 Facilitates PRV and VSV Infection by Inhibiting Type I Interferon Production

  2025cites this paper
• Acute myeloid leukemia with t(8;21) translocation: Molecular pathogenesis, potential therapeutics and future directions.

  2025cites this paper
• Synergistic activities of Panobinostat and doxorubicin in soft tissue sarcomas.

  2024cites this paper
• Natural product based anticancer drug combination discovery assisted by deep learning and network analysis

  2024cites this paper
• Mechanisms of programmed cell death: structural and functional pathways. A narrative review.

  2024cites this paper
• Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia

  2024cites this paper
• Microenvironment matters: In vitro 3D bone marrow niches differentially modulate survival, phenotype and drug responses of acute myeloid leukemia (AML) cells.

  2024cites this paper
• Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies

  2023cites this paper
• GSE1 links the HDAC1/CoREST co-repressor complex to DNA damage

  2023cites this paper
• Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas

  2022cites this paper
• LncRNA-PAX8-AS1 Silencing Decreases Cell Viability, Enhances Apoptosis, and Suppresses Doxorubicin Resistance in Myeloid Leukemia via the miR-378g/ERBB2 Axis

  2022cites this paper
• Multifaceted Influence of Histone Deacetylases on DNA Damage Repair: Implications for Hepatocellular Carcinoma

  2022cites this paper
• Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells

  2022cites this paper
• CMAR_A_346052 259..271

  2022cites this paper
• Targeted Cancer Therapy Based on Acetylation and Deacetylation of Key Proteins Involved in Double-Strand Break Repair

  2022cites this paper
• Acetylated DNMT1 Downregulation and Related Regulatory Factors Influence Metastatic Melanoma Patients Survival

  2021cites this paper
• Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines

  2021cites this paper
• Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model

  2021cites this paper
• Mitochondrial metabolism as a target for acute myeloid leukemia treatment

  2021cites this paper
• Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy

  2021cites this paper
• Dual-target inhibitors based on HDACs: Novel antitumor agents for cancer therapy.

  2020cites this paper
• Novel therapeutic strategies for MLL-rearranged leukemias.

  2020cites this paper
• Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs

  2020cites this paper
• H-RACS: a handy tool to rank anti-cancer synergistic drugs

  2020cites this paper
• Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors

  2020cites this paper
• HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.

  2020cites this paper
• Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results

  2019cites this paper
• Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1

  2019cites this paper
• Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

  2019cites this paper
• Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy

  2019cites this paper
• Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.

  2019cites this paper
• Targeting DNA repair in cancer: current state and novel approaches

  2019cites this paper
• HDAC Inhibitors in Acute Myeloid Leukemia

  2019cites this paper
• Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study

  2019cites this paper
• Histone deacetylase 6 in cancer

  2018cites this paper
• Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials

  2018cites this paper
• Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells

  2017cites this paper
• Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

  2017cites this paper
• The role of SET/I2PP2A in canine mammary tumors

  2017cites this paper
• HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia

  2016cites this paper
• Panobinostat for the treatment of acute myelogenous leukemia

  2016influential citation
• Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription

  2016cites this paper
• Gene expression profiling based identifications of potential prognostic molecular markers in decitabine treated acute myeloid leukemia

  2016cites this paper
• Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer

  2016cites this paper
• Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

  2015cites this paper
• Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.

  2014cites this paper
• Development and Application of High-throughput Chemical Genomic Screens for Functional Studies of Cancer Therapeutics

  2013cites this paper
• Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy

  2013cites this paper
• Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

  2013cites this paper
• University of Birmingham Inhibition of Plk1 and Cyclin B1 expression results in panobinostat-induced G delay and mitotic defects

  2013cites this paper
• Inhibition of Plk1 and Cyclin B1 expression results in panobinostat-induced G delay and mitotic defects G and

  2013cites this paper
• Inhibition of Plk1 and Cyclin B1 Expression Results in Panobinostat-Induced G2 Delay and Mitotic Defects

  2013cites this paper
• Diagnosis and Treatment of Adult Acute Myeloid Leukemia Other than Acute Promyelocytic Leukemia

  2013cites this paper
• Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

  2012cites this paper
• The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

  2012cites this paper
• The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment.

  2012cites this paper
• Paeoniflorin protects myocardial cell from doxorubicin-induced apoptosis through inhibition of NADPH oxidase.

  2012cites this paper
• Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity.

  2012cites this paper
• Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

  2012cites this paper
• Co-Corresponding authors:

  2011cites this paper
• Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells

  2011cites this paper
• Histone deacetylase inhibitors regulate the proteasomal degradation of oncoproteins

  2011cites this paper
• Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.

  2011cites this paper
• Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response

  2011cites this paper
• The DAC system and associations with acute leukemias and myelodysplastic syndromes

  2010cites this paper
• The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression

  2010cites this paper
• The Common Leukemic Fusions in Pathogenesis and in Treatment Response in Acute Myeloid Leukemia

  2010cites this paper
• Cancer–germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment

  2010cites this paper
• Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy

  2010cites this paper